FDA Brief

Warning letters Drugs

FDA warning letter to

Zydus Lifesciences Limited

High riskIssued Jun 2Posted Jun 9Center for Drug Evaluation and Research (CDER)

FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.

What happened

FDA reviewed records the company sent in response to an FDA request for records dated November 7, 2025 (a records request under section 704(a)(4) of the FD&C Act, not an onsite inspection). The records showed the company had not properly tested incoming talc, a drug ingredient, for asbestos, and that infrared scans lacked the scale expansions needed to detect tremolite, chlorite and serpentines. FDA also found an out-of-specification wavenumber result removed from an instrument report and passing values added, and that 21 of 29 approved talc results from 2022 to 2025 had identical maxima across different lots and dates.

What FDA found

  1. The company used talc without first showing each lot met written specifications, and its infrared test did not follow current USP methods for detecting asbestos.

    21 CFR 211.84
  2. The quality unit did not do its job: a failing infrared identification result was edited to look like a pass, and many certificates of analysis had suspiciously identical values.

    21 CFR 211.22

What FDA wants

Respond in writing within 15 working days with what you have done and will do to fix these violations. Also provide, within 30 calendar days, independent laboratory asbestos test results on retained talc lots (or finished batches if no talc retain exists), a full lab assessment and remediation plan, and a risk assessment for in-date products that may contain asbestos, including customer notices or recalls if needed.

Who should pay attention

  • US distributors and pharmacies selling Zydus prescription products
  • companies that buy talc as a drug ingredient and rely on supplier certificates of analysis
  • patients and prescribers of talc-containing prescription powders

This is a summary. Read the original letter on fda.gov.

Zydus Lifesciences Limited's FDA history

  1. Zydus Lifesciences Limited

    FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.

    High risk

Full company page

Similar letters to other companies

  1. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk
  2. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  3. Umendra Life Sciences Private Limited

    Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

    High risk
  4. Erkul Kozmetik Sanayi ve Ticaret A.S.

    Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.

    High risk